Infant Bacterial Therapeutics
Develops microbiome drugs to prevent or treat rare diseases in premature infants.
IBT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008015242 (+3 more)
- LEI:
- 2138008KVBXCRJGP6Z26
- Country:
- Sweden
- Address:
- Bryggargatan 10, 111 21 Stockholm
- Website:
- https://ibtherapeutics.com/
- Sector:
- Manufacturing
Description
Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-11-07 08:00 | English | PDF • 244.0 KB | |||
| 2019-11-05 17:00 |
Lilian Wikström Ph.D. har begärt eget utträde från styrelsen i Infant Bacterial…
|
Swedish | PDF • 106.0 KB | ||
| 2019-11-05 17:00 |
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of In…
|
English | PDF • 106.4 KB | ||
| 2019-08-22 12:45 | English | PDF • 33.7 KB | |||
| 2019-08-02 08:00 | English | PDF • 371.0 KB | |||
| 2019-07-04 14:15 |
Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotal…
|
Swedish | PDF • 109.9 KB | ||
| 2019-07-04 14:15 |
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Ph…
|
English | PDF • 111.9 KB | ||
| 2019-05-19 18:00 |
FDA och Infant Bacterial Therapeutics överens rörande Fas III studiens utformni…
|
English | PDF • 109.1 KB | ||
| 2019-05-19 18:00 |
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
|
English | PDF • 109.1 KB | ||
| 2019-05-12 13:00 | English | PDF • 342.0 KB | |||
| 2019-05-06 18:30 |
Årsstämma i Infant Bacterial Therapeutics
|
Swedish | PDF • 107.2 KB | ||
| 2019-05-06 18:30 |
Annual General Meeting of Infant Bacterial Therapeutics
|
English | PDF • 107.2 KB | ||
| 2019-05-03 17:09 |
Infant Bacterial Therapeutics AB sluter sitt första distributionsavtal
|
Swedish | PDF • 111.7 KB | ||
| 2019-05-03 17:09 |
Infant Bacterial Therapeutics AB announces first distribution agreement
|
English | PDF • 111.0 KB | ||
| 2019-04-05 17:30 |
Kallelse till årsstämma i Infant Bacterial Therapeutics
|
Swedish | PDF • 163.6 KB |
Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Infant Bacterial Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-14 | Maria Ekdahl | Other | Buy | 500 | 17,000.00 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 839 | 79,033.80 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 161 | 15,134.00 SEK |
| 2023-06-09 | Maria Ekdahl | Other | Buy | 1,086 | 49,956.00 SEK |
| 2023-05-23 | Anders Kronström | Other | Buy | 1,329 | 56,482.50 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 851 | 36,593.00 SEK |
| 2023-05-23 | Maria Ekdahl | Other | Buy | 465 | 19,995.00 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,377.20 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,269.92 SEK |
| 2023-05-22 | Maria Ekdahl | Other | Buy | 709 | 30,487.00 SEK |
Peer Companies
